You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Antibody-Dependent Cell Cytotoxicity (ADCC)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

HER2+ Advanced Breast Cancer, Other Solid Tumors Trial (ADCC-R-Epo-R T-cells + Trastuzumab, Erythropoietin beta, Fludarabine and

Not yet recruiting
  • HER2+ Advanced Breast Cancer
  • Other Solid Tumors
  • ADCC-R-Epo-R T-cells + Trastuzumab
  • +2 more
  • (no location specified)
Aug 31, 2023

Locally Advanced Breast Cancer, Chemo Effect Trial in Beijing (inetetamab with pertuzumab and paclitaxel/carboplatin (TCbIP)

Recruiting
  • Locally Advanced Breast Cancer
  • Chemotherapy Effect
  • inetetamab with pertuzumab and paclitaxel/carboplatin (TCbIP) regimen
  • Beijing, China
    National Cancer Center/National Clinical Research Center for Can
Feb 28, 2023

Breast Cancer Trial in Guangzhou (Inetetamab Plus Cyclophosphamide Metronomic Chemotherapy Plus AI)

Recruiting
  • Breast Cancer
  • Inetetamab Plus Cyclophosphamide Metronomic Chemotherapy Plus AI
  • Guangzhou, Guangdong, China
    Shusen Wang
Jul 1, 2021

Breast Cancer, Uterine Cancer, Ovarian Cancer Trial in Denmark, France, Spain (GEN1047 is a bispecific antibody that induces

Recruiting
  • Breast Cancer
  • +3 more
  • GEN1047 is a bispecific antibody that induces T-cell mediated cytotoxicity of B7H4-positive cells.
  • Copenhagen, Denmark
  • +5 more
Jul 25, 2022

Lung Cancer, Non Small Cell Lung Cancer Trial in Aurora (Amivantamab 1050mg, Amivantamab 1400mg, Amivantamab (to be determined))

Not yet recruiting
  • Lung Cancer
  • Non Small Cell Lung Cancer
  • Amivantamab 1050mg
  • +2 more
  • Aurora, Colorado
  • +2 more
Apr 25, 2023

Subclass of Donor-specific Antibody asRisk Factor of Antibody

Active, not recruiting
  • Antibody-mediated Rejection
    • Montpellier, Hérault, France
      CHU Lapeyronie
    Jan 18, 2023

    Multiple Myeloma, Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma Trial in Minneapolis (Nicotinamide Expanded Haploidentical

    Completed
    • Multiple Myeloma
    • +7 more
    • Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells
    • Minneapolis, Minnesota
      Masonic Cancer Center, University of Minnesota
    Nov 2, 2022

    Colorectal Cancer, ADCC Trial in Napoli (Folfiri/Cetuximab)

    Recruiting
    • Colorectal Cancer
    • ADCC
    • Napoli, Italy
      Istituto Nazionale dei Tumori,
    Sep 1, 2021

    Cutaneous Squamous Cell Carcinoma Trial in Waratah, Melbourne, Nedlands (Imgatuzumab)

    Suspended
    • Cutaneous Squamous Cell Carcinoma
    • Waratah, New South Wales, Australia
    • +2 more
    May 17, 2022

    Rheumatoid Arthritis, Autoimmune Rheumatologic Disease, Systemic Lupus Erythematosus Trial in Québec (COVID-19 vaccine)

    Recruiting
    • Rheumatoid Arthritis
    • +8 more
    • COVID-19 vaccine
    • Montréal, Quebec, Canada
    • +1 more
    Jan 13, 2023

    Adult T-Cell Lymphoma/Leukemia, Sezary Syndrome, Mycosis Fungoides Trial run by the NCI (Recombinant human Interleukin-15

    Completed
    Has Results
    • Adult T-Cell Lymphoma/Leukemia
    • +2 more
    • Recombinant human Interleukin-15 (rhIL-15)
    • Mogamulizumab
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Dec 9, 2022

    Lymphoma, Primary Effusion Trial run by the National Cancer Institute (NCI) (Daratumumab SC)

    Not yet recruiting
    • Lymphoma, Primary Effusion
    • Daratumumab SC
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jun 23, 2023

    Pancreatic Cancer Trial (BNT321 Dose Level 1, BNT321 Dose Level 2, mFOLFIRINOX)

    Not yet recruiting
    • Pancreatic Cancer
    • BNT321 Dose Level 1
    • +3 more
    • (no location specified)
    Sep 29, 2023

    Neuroblastoma Trial in Cologne (antibody ch14.18, GM-CSF, IL-2 i.v.)

    Terminated
    • Neuroblastoma
    • antibody ch14.18
    • +4 more
    • Cologne, Germany
      University of Cologne
    Nov 3, 2022

    HER2-positive Breast Cancer, Operable Breast Cancer Trial in France (Trastuzumab + Paclitaxel, Pegfilgrastim)

    Recruiting
    • HER2-positive Breast Cancer
    • Operable Breast Cancer
    • Avignon, France
    • +8 more
    Jan 9, 2023

    Recurrent Colon Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma Trial

    Completed
    • Recurrent Colon Carcinoma
    • +41 more
    • Cetuximab
    • +2 more
    • Columbus, Ohio
      Ohio State University Comprehensive Cancer Center
    Mar 12, 2020

    Adenoid Cystic Carcinoma of the Head and Neck Trial (OBT076, Balstilimab)

    Not yet recruiting
    • Adenoid Cystic Carcinoma of the Head and Neck
    • (no location specified)
    Jul 3, 2023

    Breast Cancer, Breast Tumors, Breast Cancer Female Trial in Germany (Ontruzant, Chemotherapy, Pertuzumab)

    Recruiting
    • Breast Cancer
    • +3 more
    • Heidelberg, Baden-Wuerttemberg, Germany
    • +10 more
    Aug 30, 2021

    Castration Resistant Prostate Cancer Trial run by the National Cancer Institute (NCI) (Bintrafusp alfa, N-803, BN-Brachyury)

    Not yet recruiting
    • Castration Resistant Prostate Cancer
    • Bintrafusp alfa
    • +2 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Feb 2, 2023

    Circulating Cluster of Differentiation 4 Positive 28 Null T

    Not yet recruiting
    • Autoimmune Hemolytic Anemia
      • (no location specified)
      Jan 31, 2023

      Advanced or Metastatic Solid Tumors Trial in Tianjin (JS012, JS012 combine with chemo)

      Recruiting
      • Advanced or Metastatic Solid Tumors
      • JS012
      • JS012 combine with chemotherapy
      • Tianjin, Tianjin, China
        Tianjin Medical University Cancer Institute & Hospital
      May 19, 2022

      Neuroblastoma Trial in Worldwide (Data-collection)

      Recruiting
      • Neuroblastoma
      • Data-collection
      • Wien,, Vienna, Austria
      • +13 more
      Oct 28, 2022

      Melanoma Trial in New York (DS-8273a, Nivolumab)

      Completed
      • Melanoma
      • DS-8273a
      • Nivolumab
      • New York, New York
        Laura and Isaac Perlmutter Cancer Center
      Oct 8, 2021

      Multiple Myeloma Trial in Worldwide (Talquetamab, Teclistamab, Daratumumab)

      Recruiting
      • Multiple Myeloma
      • Edmonton, Alberta, Canada
      • +12 more
      Jan 27, 2023

      Clear-Cell Renal Carcinoma Trial run by the NCI (rhIL-15, Avelumab)

      Terminated
      Has Results
      • Clear-Cell Renal Carcinoma
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      Apr 27, 2022